Tech Company Financing Transactions
Actinobac Biomed Funding Round
On 7/13/2017, Actinobac Biomed landed $4.4 million in funding from Foundation Venture Capital Group and Kairos Ventures.
Transaction Overview
Company Name
Announced On
7/13/2017
Transaction Type
Venture Equity
Amount
$4,400,000
Round
Undisclosed
Investors
Foundation Venture Capital Group (James Golubieski)
Proceeds Purpose
The investment from Kairos, in conjunction with funding from the National Cancer Institute, will be vital for the advancement of Leukothera into human clinical trials, eventually making it available to patients suffering from leukemia and lymphoma.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
15 Pelham Rd.
Kendall Park, NJ 08824
USA
Kendall Park, NJ 08824
USA
Phone
Website
Email Address
Overview
Actinobac is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Our drug candidates are based upon Leukothera® (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Benjamin Belinka
Chief Scientific Officer
Scott Kachlany
Browse more venture capital transactions:
Prev: 7/13/2017: Clear Ballot venture capital transaction
Next: 7/13/2017: Datavail venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs